Market revenue in 2023 | USD 207.6 million |
Market revenue in 2030 | USD 370.0 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Contract manufacturing |
Fastest growing segment | Contract Development |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Contract Manufacturing, Contract Development |
Key market players worldwide | Eurofins Scientific SE, WuXi Biologics (Cayman) Inc, Catalent Inc, AGC Inc, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Holdings Corp, Samsung BioLogics, Rentschler Biopharma SE, Recipharm |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to large molecule drug substance cdmo market will help companies and investors design strategic landscapes.
Contract manufacturing was the largest segment with a revenue share of 67% in 2023. Horizon Databook has segmented the Spain large molecule drug substance cdmo market based on contract manufacturing, contract development covering the revenue growth of each sub-segment from 2018 to 2030.
The Spanish Ministry of Health is in the process of finalizing a plan for promoting the use of biosimilar drugs. The country also heavily invests in the pharmaceutical R&D. For instance, ICEX Spain in April 2021 states that over 19.0% of industrial R&D investment is dedicated to the pharma industry.
High investment in pharma R&D and promotion of biosimilar in the country by public authorities are likely to boost the Spanish market growth. Clinical trials in Spain are regulated by the Royal Decree, but Since Spain is within the EU, its regulations need to be in line with the European Medicines Agency.
Spain is one of the prominent countries for conducting clinical trials due to presence of highly experienced research centers and investigators, proven research quality, high patient recruitment volumes, and quick study start-up. All the above factors are expected to aid market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain large molecule drug substance cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Spain large molecule drug substance cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account